PharmX TechnologiesASX:PHX 40 Net Current Asset Value is A$0.00 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 274 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 364963.14% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
PharmX Technologies's net current asset value per share for the quarter that ended in Dec. 2025 was A$0.00.
The historical rank and industry rank for PharmX Technologies's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of PharmX Technologies was 7.68. The lowest was 0.59. And the median was 2.05.
ASX:PHX's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 6.09 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PharmX Technologies (ASX:PHX) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
PharmX Technologies Net Current Asset Value Related Terms
PharmX Technologies Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for PharmX Technologies's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PHX vs VEEV, BTSG, TEM: Net Current Asset Value Comparison
For the Health Information Services subindustry, PharmX Technologies's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies Price-to-Net-Current-Asset-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of A$0.00 mean?
PharmX Technologies (ASX:PHX) has a Net Current Asset Value of A$0.00 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PharmX Technologies and its competitors. Over the past decade, PharmX Technologies' Net Current Asset Value has ranged from 0.59 to 7.68. According to the industry distribution chart, PharmX Technologies ranks #999999 out of 274 companies in the Healthcare Providers & Services industry.
Is PharmX Technologies' Net Current Asset Value too high?
PharmX Technologies' current Net Current Asset Value is A$0.00. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 7.68. Based on the distribution chart, PharmX Technologies ranks #999999 out of 274 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Net Current Asset Value compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #999999 out of 274 companies for Net Current Asset Value. This places PharmX Technologies in the lower half of its industry. The industry median Net Current Asset Value is 6.09. Historically, PharmX Technologies' own Net Current Asset Value has ranged from 0.59 to 7.68 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Healthcare Providers & Services company?
The median Net Current Asset Value among Healthcare Providers & Services companies is 6.09, based on 274 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PharmX Technologies and its competitors. For the Healthcare Providers & Services industry, the median Net Current Asset Value is 6.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current Net Current Asset Value is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.11 — trading 57.1% above its estimated fair value. The current Net Current Asset Value is A$0.00. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Net Current Asset Value is A$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.11 is trading 57.1% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
Net Current Asset Value: A$0.00
GF Value™: A$0.07 vs. price of A$0.11 (57.1% above fair value)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score
Get the complete analysis for ASX:PHX
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
